Ramsay Health Care Limited
Ramsay Health Care Limited (RHC.AX) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Ramsay Health Care Limited (RHC.AX), featuring income statements, balance sheets, and cash flow data.
Ramsay Health Care Limited (RHC.AX) Income Statement & Financial Overview
Analyze Ramsay Health Care Limited’s RHC.AX earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $8.58B | $8.09B | $7.87B | $7.11B |
| Cost of Revenue | $7.74B | $7.32B | $7.16B | $6.55B |
| Gross Profit | $838.90M | $771.80M | $709.60M | $550.40M |
| Gross Profit Ratio | $0.10 | $0.10 | $0.09 | $0.08 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $344.20M | $329.60M | $322.50M | $288.20M |
| Operating Expenses | $344.20M | $329.60M | $322.50M | $288.20M |
| Total Costs & Expenses | $8.08B | $7.65B | $7.48B | $6.84B |
| Interest Income | $2.90M | $4.10M | $16.60M | $23.30M |
| Interest Expense | $306.40M | $313.60M | $279.80M | $234.40M |
| Depreciation & Amortization | $550.90M | $531.20M | $523.90M | $476.90M |
| EBITDA | $1.05B | $1.05B | $1.004B | $1.04B |
| EBITDA Ratio | $0.12 | $0.12 | $0.12 | $0.10 |
| Operating Income | $494.70M | $442.20M | $387.10M | $262.20M |
| Operating Income Ratio | $0.06 | $0.05 | $0.05 | $0.04 |
| Other Income/Expenses (Net) | -$312.90M | -$239.40M | -$186.60M | $64.50M |
| Income Before Tax | $181.80M | $202.80M | $200.50M | $326.70M |
| Income Before Tax Ratio | $0.02 | $0.03 | $0.03 | $0.05 |
| Income Tax Expense | $54.00M | $67.30M | $79.50M | $102.00M |
| Net Income | $130.20M | $758.50M | $103.70M | $194.40M |
| Net Income Ratio | $0.02 | $0.09 | $0.01 | $0.03 |
| EPS | $0.53 | $3.29 | $0.42 | $0.83 |
| Diluted EPS | $0.53 | $3.28 | $0.42 | $0.83 |
| Weighted Avg Shares Outstanding | $228.80M | $228.30M | $228.10M | $227.80M |
| Weighted Avg Shares Outstanding (Diluted) | $229.52M | $228.80M | $228.79M | $228.20M |
Financial performance has remained strong, with revenue growing from $7.11B in Q2 2023 to $8.58B in Q4 2024. Gross profit continued to perform well, with margins at 10% in the latest quarter. Operating income reached $494.70M in Q4 2024, holding a steady 6% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at $1.05B. Net income dropped to $130.20M, keeping EPS at $0.53. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan